JP2013505968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505968A5 JP2013505968A5 JP2012531186A JP2012531186A JP2013505968A5 JP 2013505968 A5 JP2013505968 A5 JP 2013505968A5 JP 2012531186 A JP2012531186 A JP 2012531186A JP 2012531186 A JP2012531186 A JP 2012531186A JP 2013505968 A5 JP2013505968 A5 JP 2013505968A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- leukemia
- receptor
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010002386 Interleukin-3 Proteins 0.000 claims 6
- 102000000646 Interleukin-3 Human genes 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000038129 antigens Human genes 0.000 claims 6
- 108091007172 antigens Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 6
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims 6
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 206010024324 Leukaemias Diseases 0.000 claims 4
- -1 cediranib Chemical compound 0.000 claims 4
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 3
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 102000004441 Bcr-abl fusion proteins Human genes 0.000 claims 2
- 108010056708 Bcr-abl fusion proteins Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic Effects 0.000 claims 2
- 229960002448 dasatinib Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 102000006240 membrane receptors Human genes 0.000 claims 2
- 108020004084 membrane receptors Proteins 0.000 claims 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims 2
- 229960001346 nilotinib Drugs 0.000 claims 2
- 229960000241 vandetanib Drugs 0.000 claims 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N Bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- IPDMWUNUULAXLU-UHFFFAOYSA-N Damnacanthal Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=C(O)C(C=O)=C2OC IPDMWUNUULAXLU-UHFFFAOYSA-N 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 150000004922 Dasatinib derivatives Chemical group 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- 229960002412 cediranib Drugs 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 229950008835 neratinib Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24766909P | 2009-10-01 | 2009-10-01 | |
| US61/247,669 | 2009-10-01 | ||
| PCT/AU2010/001295 WO2011038467A1 (en) | 2009-10-01 | 2010-10-01 | Method of treatment of philadelphia chromosome positive leukaemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505968A JP2013505968A (ja) | 2013-02-21 |
| JP2013505968A5 true JP2013505968A5 (zh) | 2013-07-18 |
Family
ID=43825444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012531186A Pending JP2013505968A (ja) | 2009-10-01 | 2010-10-01 | フィラデルフィア染色体陽性白血病の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20120244116A1 (zh) |
| EP (1) | EP2470212A4 (zh) |
| JP (1) | JP2013505968A (zh) |
| CN (1) | CN102665756A (zh) |
| AU (1) | AU2010302961A1 (zh) |
| CA (1) | CA2775155A1 (zh) |
| IL (1) | IL218774A0 (zh) |
| WO (1) | WO2011038467A1 (zh) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1848414T3 (pl) | 2005-02-03 | 2011-10-31 | Wyeth Llc | Sposób leczenia nowotworu opornego na gefitinib |
| PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| CN102202667A (zh) | 2008-08-04 | 2011-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
| WO2010126066A1 (ja) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗IL-3Rα抗体 |
| JP6063472B2 (ja) * | 2011-11-06 | 2017-01-18 | ベータ キャット ファーマシューティカルズ リミテッド ライアビリティ カンパニー | 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 |
| JP2014533262A (ja) * | 2011-11-11 | 2014-12-11 | ファイザー・インク | 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド |
| WO2013177420A2 (en) * | 2012-05-23 | 2013-11-28 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias |
| WO2013181488A2 (en) * | 2012-06-01 | 2013-12-05 | The Ohio State University Research Foundation | Inhibition of leukemic stem cells by pp2a activating agents |
| EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| JP6612232B2 (ja) | 2013-08-28 | 2019-11-27 | クラウン バイオサイエンス インコーポレイテッド（タイカン） | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 |
| CN106170297A (zh) * | 2013-09-20 | 2016-11-30 | 纪念斯隆-凯特琳癌症中心 | 用于wt‑1‑阳性疾病的组合/辅助疗法 |
| RU2741120C2 (ru) | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| WO2017042944A1 (ja) * | 2015-09-10 | 2017-03-16 | 国立大学法人山梨大学 | フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法 |
| US10933044B2 (en) | 2016-01-13 | 2021-03-02 | Waseda University | Marine organism-derived extract, compound, and medical composition having niche formation suppressing activity of leukemic stem cells |
| KR102582752B1 (ko) | 2016-12-13 | 2023-09-22 | 프린스턴 드러그 디스커버리 인크 | 단백질 키나아제 억제제 |
| BR112020025048A2 (pt) | 2018-06-13 | 2021-04-06 | Novartis Ag | Receptores de antígeno quimérico de bcma e usos dos mesmos |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5070013A (en) * | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| DE69031914T2 (de) * | 1989-08-11 | 1998-07-30 | Amrad Corp Ltd | Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate |
| US5281699A (en) * | 1990-06-01 | 1994-01-25 | Tanox Biosystems, Inc. | Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins |
| US5112961A (en) * | 1990-07-18 | 1992-05-12 | Schering Corporation | Dna encoding subunits of a high affinity gm-csf receptor |
| EP1263463B1 (en) * | 2000-03-06 | 2011-05-25 | University of Kentucky Research Foundation | Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| WO2008052277A1 (en) * | 2006-11-03 | 2008-05-08 | St. Vincent's Institute Of Medical Research | Crystalline composition of gm-csf/gm-csfr |
| WO2008127735A1 (en) * | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| AU2008331436A1 (en) * | 2007-12-06 | 2009-06-11 | Csl Limited | Method of inhibition of leukemic stem cells |
| WO2010126066A1 (ja) * | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗IL-3Rα抗体 |
-
2010
- 2010-10-01 WO PCT/AU2010/001295 patent/WO2011038467A1/en active Application Filing
- 2010-10-01 CN CN2010800447477A patent/CN102665756A/zh active Pending
- 2010-10-01 JP JP2012531186A patent/JP2013505968A/ja active Pending
- 2010-10-01 EP EP10819752.6A patent/EP2470212A4/en not_active Withdrawn
- 2010-10-01 CA CA2775155A patent/CA2775155A1/en not_active Abandoned
- 2010-10-01 US US13/499,436 patent/US20120244116A1/en not_active Abandoned
- 2010-10-01 AU AU2010302961A patent/AU2010302961A1/en not_active Abandoned
-
2012
- 2012-03-22 IL IL218774A patent/IL218774A0/en unknown
-
2014
- 2014-10-17 US US14/517,254 patent/US20150093355A1/en not_active Abandoned
-
2016
- 2016-06-27 US US15/193,784 patent/US20160304616A1/en not_active Abandoned
-
2017
- 2017-08-30 US US15/690,826 patent/US20170362328A1/en not_active Abandoned
-
2019
- 2019-09-24 US US16/580,012 patent/US20200277389A1/en not_active Abandoned
-
2021
- 2021-03-18 US US17/205,585 patent/US20210292424A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505968A5 (zh) | ||
| CA2775155A1 (en) | Method of treatment of philadelphia chromosome positive leukemia | |
| AU2019261666B2 (en) | Uses for and article of manufacture including HER2 dimerization inhibitor Pertuzumab | |
| WO2020130125A1 (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| JP2010515709A5 (zh) | ||
| RU2010118448A (ru) | Комбинированная терапия антителами анти-cd20 типа ii в сочетании с активным агентом анти-bcl-2 | |
| JP6464085B2 (ja) | 神経膠芽腫の治療のための併用療法 | |
| AU2013243584A1 (en) | Dosage and administration of monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| EP2526934A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2008508279A5 (zh) | ||
| JP2009518447A5 (zh) | ||
| JP2014525454A5 (zh) | ||
| JP2020505433A5 (zh) | ||
| KR20190130644A (ko) | 항암 조합 요법 | |
| JP2019517485A5 (zh) | ||
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| JP2017530983A (ja) | 相乗的オーリスタチン組合せ | |
| ES2844629T3 (es) | Tratamiento de la infección por el virus de la hepatitis delta | |
| US10076512B2 (en) | Treatment of hepatitis delta virus infection | |
| JP2019525948A5 (zh) | ||
| JP2018501201A5 (zh) | ||
| CA2973857A1 (en) | Combination drug | |
| UA94213C2 (ru) | Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания |